Your session is about to expire
← Back to Search
Device
FETO Therapy for Congenital Diaphragmatic Hernia (FETO Trial)
N/A
Recruiting
Research Sponsored by Children's Hospitals and Clinics of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years of age
Awards & highlights
No Placebo-Only Group
Summary
This trial studies a new fetal procedure that hopes to increase survival rates of babies with severe CDH. It will enroll 10 pregnant people and their baby.
Who is the study for?
This trial is for pregnant women over 18 with a severe case of left-sided congenital diaphragmatic hernia in their fetus (O/E LHR < 25%). They must be at 27-29 weeks gestation, have no other lethal fetal anomalies or major heart defects, and agree to stay within 15 minutes of the Midwest Fetal Care Center.
What is being tested?
The study tests Fetoscopic Endoluminal Tracheal Occlusion (FETO) therapy on fetuses with severe CDH. It aims to increase lung volume before birth, potentially improving survival rates post-birth. The pilot will enroll ten participants to assess feasibility.
What are the potential side effects?
Potential side effects are not explicitly listed but may include risks associated with fetal surgery such as preterm labor, infection risk for both mother and baby, complications from anesthesia, and possible harm due to the balloon occlusion procedure.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 years of age
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years of age
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Successful placement of Balt Goldbal2 balloon
Successful removal of Balt Goldbal2 balloon
Secondary study objectives
Change in fetal lung growth
Gestational age at delivery
Infant survival
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: FETO therapyExperimental Treatment1 Intervention
FETO therapy
Find a Location
Who is running the clinical trial?
Children's Hospitals and Clinics of MinnesotaLead Sponsor
65 Previous Clinical Trials
5,022,229 Total Patients Enrolled
Allina Health SystemOTHER
57 Previous Clinical Trials
1,176,668 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am an adult woman pregnant with a baby diagnosed with severe left-sided CDH.I am unable to give consent by myself.My condition involves a right-sided or bilateral diaphragmatic hernia.My condition does not involve life-threatening anomalies, genetic variants, or abnormal chromosome numbers.It's not possible or safe for me to have a balloon placed via fetoscopy.I am pregnant and have tested positive for HIV, Hepatitis B, or Hepatitis C.My baby has been diagnosed with a condition that could affect their health after birth.
Research Study Groups:
This trial has the following groups:- Group 1: FETO therapy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.